ImmuCell Corp (ICCC) stock

ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3016% above fair value

$10.22+0.03 (+0.29%)

Close on Nov 12, 2026Market cap $92.82MP/E 51.1Yield –

ImmuCell EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

ImmuCell's EV/EBITDA was 14.6× on Nov 11, 2026, against 9.7× a year earlier. Over the last 5 years it ranged from 5.5× to 253.4×, with a median of 17.7×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	14.6×	+2.6
2025	Dec 31, 2025	12.0×	−126.5
2022	Oct 31, 2022	138.6×	+18.9
2018	Jan 31, 2018	119.6×	−25.6
2017	Dec 29, 2017	145.3×	+134.2
2016	Dec 30, 2016	11.0×	+1.7
2015	Dec 31, 2015	9.4×	−27.9
2014	Jan 31, 2014	37.3×	+0.3
2013	Dec 31, 2013	37.0×	+6.3
2012	Dec 31, 2012	30.7×	–

Where these numbers come from

Parsed from the XBRL in ImmuCell's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jul 25, 1990
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ICCC.

Compare: ICCC vs TKNO · ICCC vs TRIB · ICCC vs ZOMDF · ICCC vs JAGX · ICCC vs BMRA

Revenue growth19.6% · median 23.4%

Gross margin40.8% · median 50.2%

Operating margin14.5% · median -69.3%

Net margin5.7% · median -41.4%

Company	Revenue	Growth
TKNO	$45.95M	+15.4%
ZOMDF	$38.68M	+31.3%
ICCC	$33.21M	+19.6%
JAGX	$27.82M	+135.5%
BMRA	$4.34M	-11.2%
TRIB	–	–

Company

Next earnings (est.): Mar 3, 2027, after close
Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 73
Held by institutions: 14.7%
Auditor: Wipfli LLP
SEC CIK: 811641

Advertisement
300 × 250

See a number that looks wrong?